user

Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

被引：0
|
作者：
Carole Dembek
Leigh Ann White
Jayson Quach
Andrea Szkurhan
Nazia Rashid
M. R. Blasco
机构：
[1] Avalere Health,
[2] Biogen Idec,undefined
[3] Dymaxium,undefined
[4] Hospital Universitario Puerta de Hierro,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Multiple sclerosis; Cost-effectiveness; Disease-modifying therapies; Interferon-beta; I1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 362
页数：9
相关论文
共 50 条
  • [31] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Spelman, Timothy
    Herring, William L.
    Zhang, Yuanhui
    Tempest, Michael
    Pearson, Isobel
    Freudensprung, Ulrich
    Acosta, Carlos
    Dort, Thibaut
    Hyde, Robert
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    De Luca, Giovanna
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Granella, Franco
    Lechner-Scott, Jeannette
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Rozsa, Csilla
    Boz, Cavit
    Hupperts, Raymond
    Van Pesch, Vincent
    Oreja-Guevara, Celia
    van der Walt, Anneke
    Jokubaitis, Vilija G.
    Kalincik, Tomas
    Butzkueven, Helmut
    [J]. PHARMACOECONOMICS, 2022, 40 (03) : 323 - 339
  • [32] The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment
    Ceri J. Phillips
    [J]. CNS Drugs, 2004, 18 : 561 - 574
  • [33] The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment
    Phillips, CJ
    [J]. CNS DRUGS, 2004, 18 (09) : 561 - 574
  • [34] Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
    Eagle, Tessa
    Stuart, Fiona
    Chua, Alicia S.
    LaRussa, Allison
    Leclaire, Kaitlynne
    Cook, Sandra L.
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie I.
    Healy, Brian C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 196 - 201
  • [35] Comparative effectiveness of ublituximab versus other disease-modifying therapies in patients with relapsing multiple sclerosis
    Smith, N.
    Jeyakumar, S.
    Miskin, H.
    Mok, K.
    Mehta, R.
    Beckerman, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 579 - 580
  • [36] Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
    Kim, Su-Hyun
    Park, Min Su
    Kim, Woojun
    Huh, So-Young
    Shin, Hyun-June
    Hyun, Jae-Won
    Kim, Ho Jin
    [J]. JOURNAL OF CLINICAL NEUROLOGY, 2019, 15 (01): : 20 - 26
  • [37] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [38] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review
    Gallehzan, Nasrin Abulhasanbeigi
    Khosravi, Majid
    Jamebozorgi, Khosro
    Mir, Nazanin
    Jalilian, Habib
    Soleimanpour, Samira
    Hoseini, Saeed
    Rezapour, Aziz
    Eshraghi, Abbas
    [J]. HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [39] COST-EFFECTIVENESS OF NEW THERAPIES FOR MULTIPLE SCLEROSIS IN SPAIN
    Boix, B.
    Figueras, M.
    Riera, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A757 - A757
  • [40] The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis
    Freedman, M. S.
    Duquette, P.
    Grand'Maison, F.
    Lee, L.
    Vorobeychik, G.
    Lara, N.
    Khurana, V
    Nakhaipour, H. R.
    Schecter, R.
    Haddad, P.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 767 - 776
12345